Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Time to clinical response, a proxy for hospital “discharge readiness,” was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical respons...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodise, Thomas, Colman, Sam, Stein, Daniel S, Fitts, David, Goldberg, Lisa, Alexander, Elizabeth, Scoble, Patrick J, Schranz, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240345/
https://www.ncbi.nlm.nih.gov/pubmed/32462049
http://dx.doi.org/10.1093/ofid/ofaa145
_version_ 1783536862186438656
author Lodise, Thomas
Colman, Sam
Stein, Daniel S
Fitts, David
Goldberg, Lisa
Alexander, Elizabeth
Scoble, Patrick J
Schranz, Jennifer
author_facet Lodise, Thomas
Colman, Sam
Stein, Daniel S
Fitts, David
Goldberg, Lisa
Alexander, Elizabeth
Scoble, Patrick J
Schranz, Jennifer
author_sort Lodise, Thomas
collection PubMed
description Time to clinical response, a proxy for hospital “discharge readiness,” was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups.
format Online
Article
Text
id pubmed-7240345
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72403452020-05-26 Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials Lodise, Thomas Colman, Sam Stein, Daniel S Fitts, David Goldberg, Lisa Alexander, Elizabeth Scoble, Patrick J Schranz, Jennifer Open Forum Infect Dis Brief Report Time to clinical response, a proxy for hospital “discharge readiness,” was compared between CABP inpatients who received lefamulin or moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) trials. The analysis included 926 inpatients. A short and comparable median time to clinical response (4 days) was observed in both treatment groups. Oxford University Press 2020-04-24 /pmc/articles/PMC7240345/ /pubmed/32462049 http://dx.doi.org/10.1093/ofid/ofaa145 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Lodise, Thomas
Colman, Sam
Stein, Daniel S
Fitts, David
Goldberg, Lisa
Alexander, Elizabeth
Scoble, Patrick J
Schranz, Jennifer
Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
title Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
title_full Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
title_fullStr Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
title_full_unstemmed Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
title_short Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
title_sort post hoc assessment of time to clinical response among adults hospitalized with community-acquired bacterial pneumonia who received either lefamulin or moxifloxacin in 2 phase iii randomized, double-blind, double-dummy clinical trials
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7240345/
https://www.ncbi.nlm.nih.gov/pubmed/32462049
http://dx.doi.org/10.1093/ofid/ofaa145
work_keys_str_mv AT lodisethomas posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials
AT colmansam posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials
AT steindaniels posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials
AT fittsdavid posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials
AT goldberglisa posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials
AT alexanderelizabeth posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials
AT scoblepatrickj posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials
AT schranzjennifer posthocassessmentoftimetoclinicalresponseamongadultshospitalizedwithcommunityacquiredbacterialpneumoniawhoreceivedeitherlefamulinormoxifloxacinin2phaseiiirandomizeddoubleblinddoubledummyclinicaltrials

Ejemplares similares